AUSTRALIAN medicines marketing company Clinect has secured an agreement with German-based pharmaceutical company Grunenthal, giving it the exclusive marketing and distribution rights to Qutenza in Australia.
Qutenza is a topical 8% capsaicin patch indicated for the management of peripheral neuropathic pain, and has been approved in the US and EU.
Under the agreement, Clinect will be responsible for obtaining marketing authorisation for the product.
"We firmly believe in the benefits that this non-opioid treatment option can provide to people suffering from peripheral neuropathic pain and continue to work on expanding its footprint to reach more patients worldwide," said Jan Adams, CCO at Grunenthal.
"Clinect is an experienced specialist with a strong presence in Australia, and I look forward to joining forces with their team to bring our brand to Australia, a major market of the Asia-Pacific region."
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Feb 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Feb 26
